Craft

Emmaus Life Sciences

Stock Price

$0

2024-10-29

Market Capitalization

$2.4 M

2024-10-29

Revenue

$12.5 M

FY, 2025

Emmaus Life Sciences Summary

Company Summary

Overview
Emmaus Life Sciences is a biopharmaceutical company that provides treatments and therapies for rare and orphan diseases. It focuses on such genetic disorders as sickle cell disease. The company develops an oral pharmaceutical grade L-glutamine treatment for sickle cell anemia and sickle ß0-thalassemia.
Type
Public
Status
Active
Founded
2000
HQ
Torrance, CA, US | view all locations
Website
https://www.emmausmedical.com/
Cybersecurity rating
Sectors

Key People

  • Yasushi Nagasaki, Senior Vice President of Finance

    • Robert Dickey, Director, Chair of the Audit Committee

      • Dale E. Short, General Counsel

        LocationsView all

        1 location detected

        • Torrance, CA HQ

          United States

          21250 Hawthorne Blvd #800

        Emmaus Life Sciences Financials

        Summary Financials

        Revenue (Q1, 2026)
        $2.0M
        Gross profit (Q1, 2026)
        $1.8M
        Net income (Q1, 2026)
        ($3.3M)
        Cash (Q1, 2026)
        $1.1M
        EBIT (Q1, 2026)
        ($823.0K)
        Enterprise value
        $20.4M

        Footer menu